Progress towards optimal trial end-points in rheumatoid arthritis

Area of Science:

• Rheumatology
• Clinical Trial Methodology

Background:

• Clinical trials in rheumatoid arthritis (RA) have faced challenges due to inconsistent outcome measures.
• The Outcome Measures in Rheumatology (OMERACT) consensus conferences aimed to standardize measurement in RA research.

Purpose of the Study:

• To review frequently used measures in RA clinical trials.
• To assess the validity of these measures within the OMERACT framework.
• To highlight the development and adoption of standardized outcome sets for RA research.

Main Methods:

• Review of existing literature on RA outcome measures.
• Analysis of recommendations from OMERACT consensus conferences.
• Examination of the components of the World Health Organization/International League of Associations for Rheumatology (WHO/ILAR) core set.

Main Results:

• The WHO/ILAR core set, including pain, patient and physician global assessment, physical disability, swollen and tender joints, and acute phase reactants, is now a minimum standard for RA trials.
• Radiographs are included for long-term studies (≥1 year).
• There is increasing interest in aggregate endpoints (indices), adverse effect measurement, and economic costs.

Conclusions:

• Standardized measurement in RA has significantly improved, facilitating the interpretation of clinical trial results.
• These advancements are timely, supporting the evaluation of new and emerging RA treatments.
• The adoption of core sets enhances the reliability and comparability of RA research globally.